The paradigm shift in the approach to management of latent tuberculosis infection in high tuberculosis burden countries

References

• World Health Organization. Global tuberculosis report 2019. Geneva, Switzerland: WHO; 2019.
   Google Scholar
• Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nat Rev Dis Primers. 2016;2:16076.
   PubMed Web of Science ®Google Scholar
• Sloot R, van der Loeff SMF, Kouw PM, et al. Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam. Am J Respir Crit Care Med. 2014;190:1044–1052.
   PubMed Web of Science ®Google Scholar
• Behr MA, Edelstein PH, Ramakrishnan L. Revisiting the timetable of tuberculosis. BMJ. 2018;362:k2738.
   PubMedGoogle Scholar
• Lileback T, Dirksen A, Baess I, et al. Molecular evidence of endogenous reactivation of mycobacterium tuberculosis after 33 years of latent infection. J Infect Dis. 2002;185(3):401–404.
   PubMed Web of Science ®Google Scholar
• Political declaration of the High-Level Meeting of the General Assembly on the Fight Against Tuberculosis. UN general assembly 73rd session; 2018 cited 2020 Apr 15. http://digitallibrary.un.org/record/1649568
   Google Scholar
• Achkar JM, Jenny-Avital ER. Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response. J Infect Dis. 2011;204(suppl 4):S1179–86.
   PubMedGoogle Scholar
• Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152.
   PubMed Web of Science ®Google Scholar
• Knight GM, McQuaid CF, Dodd PJ, et al. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modeling. Lancet Infect Dis. 2019;19(8):903–912.
   PubMed Web of Science ®Google Scholar
• Getahun H, Matteelli A, Chaisson RE, et al. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127–2135.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva, Switzerland: WHO; 2018. WHO/CDS/TB/2018.4
   Google Scholar
• Gupta A, Montepiedra G, Aaron L, et al. Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med. 2019;381:1333–1346.
   PubMed Web of Science ®Google Scholar
• WHO operational handbook on tuberculosis. Module 1: prevention - tuberculosis preventive treatment. Geneva: World Health Organization; 2020.
   Google Scholar
• Charan J, Goyal JP, Reljic T, et al. Isoniazid for the prevention of tuberculosis in HIV-infected children: a systematic review and meta-analysis. Pediatr Infect Dis. 2018;37:773–780.
   Google Scholar
• Martinez L, Cords O, Horsburgh CR, et al. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet. 2020;395(10228):973–984.
   PubMed Web of Science ®Google Scholar
• Getahun H, Matteelli A, Abubackar I, et al. Management of latent mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46(6):1563–1576.
   PubMed Web of Science ®Google Scholar
• Implementing the WHO Stop TB Strategy: a handbook for national tuberculosis control programs. Geneva, World Health Organization, 2008 (WHO/HTM/TB/2008.401)
   Google Scholar
• Padmapriyadarsini C, Das M, Nagaraja SB, et al. Is chemoprophylaxis for child contacts of drug-resistant TB patients beneficial? A systematic review. Tuberc Res Treat. 2018;2018: 1–8. Article ID 3905890.
   Google Scholar
• Bamrah S, Brostrom R, Dorina F, et al. Treatment for LTBI in contacts of MDR-TB patients, federated states of Micronesia, 2009-2012. Int J Tuberc Lung Dis. 2014;18(8):912–918.
   PubMed Web of Science ®Google Scholar
• Khan PY, Yates TA, Osman M, et al. Transmission of drug-resistant tuberculosis in HIV-endemic settings. Lancet Infect. 2019;19(3):e77–e88.
   Google Scholar
• Fox GJ, Schaaf HS, Mandalakas A, et al. Preventing the spread of multidrug-resistant tuberculosis and protecting contacts of infectious cases. Clin Microbiol Infect. 2017;23(3):147–153.
   PubMed Web of Science ®Google Scholar
• Hamada Y, Lujan J, Schenkel K, et al. Sensitivity and specificity of WHO’s recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018;5(9):E515–23.
   PubMed Web of Science ®Google Scholar
• Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27(1):3–20.
   PubMed Web of Science ®Google Scholar
• Chandrasekaran P, Mave V, Thiruvengadam K, et al. Tuberculin skin test and QuantiFERON-gold in tube assay for diagnosis of latent TB infection among household contacts of pulmonary TB patients in high TB burden setting. PLoS One. 2018;13(8):e0199360.
   PubMed Web of Science ®Google Scholar
• Haas MK, Belknap RW. Diagnostic tests for latent tuberculosis infection. Clin Chest Med. 2019;40(4):829–837.
   PubMed Web of Science ®Google Scholar
• Won D, Park JY, Kim HS, et al. Comparative results of QuantiFERON-TB gold in-tube and quantiFERON-TB gold plus assays for detection of tuberculosis infection in clinical samples. J Clin Microbiol. 2020;58(4):e-01854-19.
   PubMed Web of Science ®Google Scholar
• Behr MA, Edelstein PH, Ramakrishnan L. Is Mycobacterium tuberculosis infection life long? BMJ. 2019;367:l5770.
   PubMedGoogle Scholar
• Bella CD, Spinicci M, Alnwaisri HFM, et al. LIOFeron®TB/LTBI: a novel and reliable test for LTBI and tuberculosis. Int J Infect Dis. 2020;91:177–181.
   PubMed Web of Science ®Google Scholar
• Brantestig S, Kinnunen A, Almeflo S, et al. Comparative evaluation of CLIA and EIA for quantiferon-TB Gold Plus. APMIS. 2020;128(4):343–349.
   PubMed Web of Science ®Google Scholar
• Ruhwald M, Aggerbeck H, Gallardo RV, et al. Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: a phase 3, double-blind, randomized, controlled trial. Lancet Respir Med. 2017;5(4):259–268.
   PubMed Web of Science ®Google Scholar
• Deng M, Lv XD, Fang ZX, et al. The blood transcriptional signature for active and latent tuberculosis. Infect Drug Resist. 2019;12:321–328.
   PubMed Web of Science ®Google Scholar
• Wang S, He L, Wu J, et al. Transcriptional profiling of human peripheral blood mononuclear cells identifies diagnostic biomarkers that distinguish active and latent tuberculosis. Front Immunol. 2019;10:2948.
   PubMed Web of Science ®Google Scholar
• Wawrocki S, Seweryn M, Kielnierowski G, et al. IL-18/IL-37/IP-10 signalling complex as a potential biomarker for discriminating active and latent TB. PLoS One. 2019;14(12):e0225556.
   PubMed Web of Science ®Google Scholar
• Gupta RK, Turner CT, Venturini C, et al. Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. Lancet Respir Med. 2020;8(4):395–406.
   PubMed Web of Science ®Google Scholar
• Zak DE, Penn-Nicholson A, Scriba TJ, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet. 2016;387(10035):2312–2322.
   PubMed Web of Science ®Google Scholar
• Thompson EG, Du Y, Malherbe ST, et al. Host blood RNA signatures predict the outcome of tuberculosis treatment. Tuberculosis (Edinb). 2017;107:48–58.
   PubMed Web of Science ®Google Scholar
• Goletti D, Lee MR, Wang JY, et al. Update on tuberculosis biomarkers: from correlates of risk to correlates of active disease and of cure from disease. Respirology. 2018;23:455–466.
   PubMed Web of Science ®Google Scholar
• Silveira-Mattos PS, Barreto-Duarte B, Vasconcelos B, et al. Differential expression of activation markers by Mycobacterium tuberculosis-specific CD4+ T-cell distinguishes extrapulmonary from pulmonary tuberculosis and latent infection. Clin Infect Dis.  2020;71(8):1905–11.
   Web of Science ®Google Scholar
• Petersen E, Chakaya J, Jawad FM, et al. Latent tuberculosis infection: diagnostic tests and when to treat. Lancet Infect Dis. 2019;19(3):231–233.
   PubMed Web of Science ®Google Scholar
• Yuen CM, Seddon JA, Keshavjee S, et al. Risk-benefit analysis of tuberculosis infection testing for household contact management in high-burden countries: a mathematical modeling study. Lancet Glob Health. 2020;8(5):e672–80.
   PubMed Web of Science ®Google Scholar
• Boon SD, Matteelli A, Ford N, et al. Continuous Isoniazid for the Treatment of Latent Tuberculosis Infection in People Living With HIV. AIDS. 2016;30(5):797–801.
   PubMed Web of Science ®Google Scholar
• Harries AD, Kumar AMV, Satyanarayana S, et al. Treatment for latent tuberculosis infection in low- and middle-income countries: progress and challenges with implementation and scale-up. Expert Rev Respir Med. 2020;14(2):195–208.
   PubMed Web of Science ®Google Scholar
• Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379:440–453.
   PubMed Web of Science ®Google Scholar
• Diallo T, Adjobimey M, Ruslami R, et al. Safety and Side Effects of Rifampin versus Isoniazid in Children. N Engl J Med. 2018;379(5):454–463.
   PubMed Web of Science ®Google Scholar
• Zenner D, Beer N, Harris RJ, et al. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med. 2017;167:248–255.
   PubMed Web of Science ®Google Scholar
• Sun HY, Huang YW, Huang WC, et al. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: a multicenter randomized controlled trial in Taiwan. Tuberculosis (Edinb). 2018;111:121–126.
   PubMed Web of Science ®Google Scholar
• Doan TN, Fox GJ, Meehan MT, et al. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study. J Antimicrob Chemother. 2019;74(1):218–227.
   PubMed Web of Science ®Google Scholar
• Johnson KT, Churchyard GJ, Sohn H, et al. Cost-effectiveness of preventive therapy for tuberculosis with isoniazid and rifapentine versus isoniazid alone in high-burden settings. Clin Infect Dis. 2018;67:1072–1078.
   PubMed Web of Science ®Google Scholar
• Swindells A, Ramachandran R, Gupta A, et al. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380(11):1001–1011.
   PubMed Web of Science ®Google Scholar
• Badje A, Moh R, Gabillard D, et al. Effect of isoniazid preventive therapy on risk of death in West African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–89.
   PubMed Web of Science ®Google Scholar
• Fernandez LG, Casas EC, Singh S, et al. New opportunities in tuberculosis prevention: implications for people living with HIV. J Int AIDS Soc. 2020;23(1):e25438.
   PubMed Web of Science ®Google Scholar
• Xavier MS, Trajman A, Schmaltz CAS, et al. Daily 800 Mg versus 600 Mg efavirenz for HIV patients treating tuberculosis with a rifampicin-based regimen: an open-label randomized controlled trial. Biomed Res Int. 2018;9231835:2018.
   Google Scholar
• Trieu L, Proops DC, Ahuja SD. Moxifloxacin prophylaxis against MDR TB, New York, New York, USA. Emerg Infect Dis. 2015;21(3):500–503.
   PubMed Web of Science ®Google Scholar
• Marks SM, Mase SR, Morris SB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis. Clin Infect Dis. 2017;64(12):1670–1677.
   PubMed Web of Science ®Google Scholar
• Abad CL, Deziel PJ, Razonable RR. Treatment of latent TB infection and the risk of tuberculosis after solid organ transplantation: comprehensive review. Transpl Infect Dis. 2019;21(6):e13178.
   PubMedGoogle Scholar
• Silva JT, san-Juan R, Fernandez-Ruiz M, et al. Fluoroquinolones for the treatment of latent mycobacterium tuberculosis infection in liver transplantation. World J Gastroenterol. 2019;25(26):3291–3298.
   PubMed Web of Science ®Google Scholar
• Torre-Cisneros J, San-Juan R, Rosso-Fernández CM, et al. Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with a high incidence of tenosynovitis: safety analysis of a multicenter randomized trial. Clin Infect Dis. 2015;60(11):1642–1649.
   PubMed Web of Science ®Google Scholar
• Tien V, Robilotti E, Callister D, et al. Tolerability of fluoroquinolones in management of latent tuberculosis in liver transplant candidates. Clin Infect Dis. 2015;61:1631–1632.
   PubMed Web of Science ®Google Scholar
• Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440–453.
   PubMed Web of Science ®Google Scholar
• Yew WW. Clinically significant interactions with drugs used in the treatment of Tuberculosis. Drug Saf. 2002;25(2):111–133.
   PubMed Web of Science ®Google Scholar
• Pease C, Hutton B, Yazdi F, et al. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. Pharmacoepidemiol Drug Saf. 2018;27(6):557–566.
   PubMed Web of Science ®Google Scholar
• Huguet A, Ader F, Ohlmann C, et al. Drug-induced fulminant hepatitis in a child treated for latent multidrug-resistant tuberculosis with dual therapy combining pyrazinamide and levofloxacin. Pediatr Infect Dis J. 2019;38(10):1025–1026.
   PubMed Web of Science ®Google Scholar
• Tasillo A, Salomon JA, Trikalinos TA, et al. Cost-effectiveness of testing and treatment for latent tuberculosis infection in residents born outside the united states with and without medical comorbidities in a simulation model. JAMA Intern Med. 2017;177(12):1755–1764.
   PubMed Web of Science ®Google Scholar
• Greenaway C, Pareek M, Chakra CAN, et al. The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review. Euro Surveill. 2018;23(14):17–00543.
   Google Scholar
• Johnson KT, Churchyard GJ, Sohn H, et al. Cost-effectiveness of preventive therapy for tuberculosis with isoniazid and rifapentine versus isoniazid alone in high-burden settings. Clin Infect Dis. 2018;67(7):1072–1078.
   PubMed Web of Science ®Google Scholar
• Kapoor S, Gupta A, Shah M. Cost-effectiveness of isoniazid preventive therapy for HIV-infected pregnant women in India. Int J Tuberc Lung Dis. 2016;20(1):85–92.
   PubMed Web of Science ®Google Scholar
• Marx FM, Cohen T, Menzies NA, et al. Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis. Lancet Glob Health. 2020;8:e1223–33.
   PubMed Web of Science ®Google Scholar
• Marks SM, Mase SR, Morris SB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis. Clin Infect Dis. 2017;64(12):1670–1677.
   PubMed Web of Science ®Google Scholar
• Fox GJ, Oxlade O, Menzies D. Fluoroquinolone therapy for the prevention of multidrug-resistant tuberculosis in contacts. a cost-effectiveness analysis. Am J Respir Crit Care Med. 2015;192(2):229–237.
   PubMed Web of Science ®Google Scholar
• Sharma SK, Mohanan S, Sharma A. Relevance of latent TB infection in areas of high TB prevalence. Chest. 2012;142(3):761–773.
   PubMed Web of Science ®Google Scholar
• Faust L, Ruhwald M, Schumacher S, et al. How are high burden countries implementing policies and tools for latent tuberculosis infection? A survey of current practices and barriers. Health Sci Rep. 2020;3:e158.
   PubMedGoogle Scholar
• Szkwarko D, Hirsch-Moverman Y, Du Plessis L, et al. Child contact management in high tuberculosis burden countries: a mixed-methods systematic review. PLoS ONE. 2017;12(8):e0182185.
   PubMed Web of Science ®Google Scholar
• Tait DR, Hatherill M, Meeren OVD, et al. Final analysis of a trial of M72/AS01 E vaccine to prevent tuberculosis. N Engl J Med. 2019;381(25):2429–2439.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Chest radiography in tuberculosis detection. Geneva, Switzerland: WHO; 2016 (WHO/HTM/TB/2016.20) (2016).
   Google Scholar
• Reddy MM, Thekkur P, Ramya N, et al. To start or to complete? – challenges in implementing tuberculosis preventive therapy among people living with HIV: a mixed-methods study from Karnataka, India. Glob Health Action. 2020;13(1):1704540.
   PubMed Web of Science ®Google Scholar
• Alsdurf H, Hill PC, Matteelli A, et al. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16:1269–1278.
   PubMed Web of Science ®Google Scholar
• Ayele HT, van Mourik MS, Bonten MJ. Predictors of adherence to isoniazid preventive therapy in people living with HIV in Ethiopia. Int J Tuberc Lung Dis. 2016;20:1342–1347.
   PubMed Web of Science ®Google Scholar
• Chopra KK, Arora VK, Singh S. COVID 19, and tuberculosis. Indian J Tuberc. 2020;67(2):149–151.
   PubMedGoogle Scholar
• Tadolini M, Codecasa LR, García-García J-M, et al. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J. 2020;56:2001398.
   PubMed Web of Science ®Google Scholar